COMMUNIQUÉS West-GlobeNewswire

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
27/05/2025
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today [...]
See All AI Raises $33 Million to Bring Revolutionary AI-Based Sliceable Intraoperative 3D Visualization and Advanced Navigation to Global Healthcare
27/05/2025
Groundbreaking platform generates high-resolution 3D models with 1mm cross-sectional slices from as few as two intraoperative fluoroscopic X-ray images, eliminates the need for pre-operative scans, and delivers precise [...]
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
27/05/2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced [...]
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
27/05/2025
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of [...]
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
27/05/2025
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program [...]
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
27/05/2025
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines [...]
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
27/05/2025
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest – – LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; [...]
NewGen Announces Strategic Expansion with Services Tailored for Indian Medical Tourists
27/05/2025
First Fertility PGS Center Limited launches culturally tailored fertility services in Thailand's growing medical tourism sector BANGKOK, May 27, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” [...]
Algernon Announces $1M Private Placement
27/05/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: [...]
Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease
27/05/2025
AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on [...]
EDAP to Present at the Jefferies Global Healthcare Conference
27/05/2025
AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a [...]
Strüngmann Award Committee Announces 2025 Finalists Recognizing Outstanding Life Science Entrepreneurs in the DACH Region
27/05/2025
The selected finalists have demonstrated entrepreneurial execution and translational potential for a range of scientific approaches The winner(s) will be officially announced on July 3, 2025, and will receive an EUR 100 [...]
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
27/05/2025
Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177 Lu-edotreotide (ITM-11), following positive Phase 3 results Flexible funding structure enables continued advancement of ITM’s targeted [...]
Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC
27/05/2025
Further Validates Cryptigens™ as Actionable Targets for Cancer Immunotherapy MONTREAL and CAMBRIDGE, United Kingdom, May 27, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapy company, and Institute [...]
Epitopea annonce un article dans Nature Cancer sur de nouvelles cibles d'immunothérapie dans le mélanome et le cancer du poumon non à petites cellules (NSCLC)
27/05/2025
Validation supplémentaire des Cryptigens™ en tant que cibles exploitables pour l'immunothérapie du cancer MONTRÉAL et CAMBRIDGE, Royaume-Uni, 27 mai 2025 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique [...]
dacadoo Launches Generation 5 of Its Award-Winning Digital Health Engagement Platform
27/05/2025
Zurich, CH, May 27, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement technology since 2010 with over 100 granted patents, announces the launch of Generation 5 of its Digital Health [...]
C4X Discovery receives latest milestone payment from Sanofi
27/05/2025
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it has [...]
Salvia BioElectronics Secures $60M in Oversubscribed Series B to Bring its Pioneering Migraine Therapy to Market
27/05/2025
Series B funding round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM) and [...]
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment
27/05/2025
Press release CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment CROSSJECT developed the ZENEO® Nest , a new [...]

Pages